The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Procedure for pooling clinical outcome data from DRUP-like clinical trials using the OMOP model.
 
Henk van der Pol
No Relationships to Disclose
 
Tina Kringelbach
Stock and Other Ownership Interests - Gubra; Novo Nordisk
Research Funding - GlaxoSmithKline (Inst); Incyte (Inst); Roche (Inst)
 
Gro Live Fagereng
No Relationships to Disclose
 
Gabriel Stav
No Relationships to Disclose
 
Maria Agudo
No Relationships to Disclose
 
Soemeya Haj Mohammad
No Relationships to Disclose
 
Florentine Verbeek
No Relationships to Disclose
 
Hans Timmer
No Relationships to Disclose
 
Loic Verlingue
Leadership - Resolved
Consulting or Advisory Role - Adaptherapy
Research Funding - Bristol-Myers Squibb
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen; Zai lab
Speakers' Bureau - BMS; Eisai; Guardant Health; Janssen; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; BMS; Immutep; Janssen; Roche; Roche; Zai Lab
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Katriina Jalkanen
Employment - Faron Pharmaceuticals (I)
Stock and Other Ownership Interests - Faron Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Bayer (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Kristoffer Rohrberg
Honoraria - MSD; MSD
Consulting or Advisory Role - Abbvie; Genmab
Research Funding - Alligator Bioscience (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Merus (Inst); MonTa Biosciences (Inst); MSD (Inst); Navire (Inst); Novartis (Inst); Orion Clinical (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Symphogen (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst)
 
Henk Verheul
No Relationships to Disclose
 
Ulrik Lassen
Honoraria - Bayer; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Pfizer
Research Funding - BMS (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Aslaug Helland
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); GlaxoSmithKline (Inst); Illumina (Inst); InCyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Ultimovacs (Inst)
 
Emile Voest
Leadership - Mosaic Therapeutics; Sanofi
Stock and Other Ownership Interests - Mosaic Therapeutics; Sanofi
Consulting or Advisory Role - Biogeneration Ventures; InteRNA
Research Funding - astrazeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
 
Eivind Hovig
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - Abbisko Therapeutics (Inst); AmmaxBio (Inst); Blueprint Medicines (Inst); Deciphera (Inst); InhibRx (Inst); Ipsen (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Abbisko Therapeutics (Inst); Merck (Inst)
 
Kjetil Tasken
Stock and Other Ownership Interests - Ledidi; Serca Pharmaceuticals
Consulting or Advisory Role - Serca Pharmaceuticals
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Stock and Stock options, and royalty agreement through Oslo University Hospital / University of Oslo Tech Transfer Office Inven2 AS.
Travel, Accommodations, Expenses - Roche